References
- Hovding, G. : Acute bacterial conjunctivitis. Acta Ophthalmol. 86, 5 (2008).
- Granet, D. B., Dorfman, M. and Stroman, D. : A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J. Pediatr. Ophthalmol. Strabismus 45, 340 (2008). https://doi.org/10.3928/01913913-20081101-07
- 건강보험심사평가원 : 2008년 진료비통계지표. Available at http://www.hira.or.kr/common/dummy. jsp?pgmid=HIRAF010303000000 (Accessed Feb 11, 2010).
- 건강보험심사평가원 : 병원.질병정보. 다빈도질병. Available at http://www.hira.or.kr/rdd_disease.do?method=listHifreqdiseinfo&pgmid=HIRAA020200000000 (Accessed Feb 11, 2010).
- Weiss, A., Brinser, J. H. and Nazar-Stewart, V. : Acute conjunctivitis in children. J. Pediatr. 122, 10 (1993). https://doi.org/10.1016/S0022-3476(05)83479-1
- Tepedino, M. E., Heller, W. H., Usner, D. W., Brunner, L. S., Morris, T. W., Haas, W., Paterno, M. R. and Comstock, T. L. : Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25, 1159 (2009). https://doi.org/10.1185/03007990902837919
- Lichtenstein, S. J., Wagner, R. S., Jamison, T., Bell, B. and Stroman, D. W. : Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv. Ther. 24, 1098 (2007). https://doi.org/10.1007/BF02877716
- Sheikh, A. and Hurwitz, B. : Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2, CD001211 (2006).
- McDonald, M. B., Protzko, E. E., Brunner, L. S., Morris, T. W., Haas, W., Paterno, M. R., Comstock, T. L. and Usner, D. W. : Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 116, 1615 (2009). https://doi.org/10.1016/j.ophtha.2009.05.014
- Egger, S. F., Ruckhofer, J. and Alzner, E. : In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res. 33, 117 (2001). https://doi.org/10.1159/000055655
- Kaliamurthy, J., Nelson Jesudasan, C. A. and Geraldine, P. : Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res. 37, 117 (2005).
- Ward, K. W., Lepage, J. F. and Driot, J. Y. L. : Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL- 303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacal. Ther. 23, 243 (2007). https://doi.org/10.1089/jop.2006.0137
- Hwang, D. G. : Fluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolones. Surv. Ophthalmol. 49, S79 (2004). https://doi.org/10.1016/j.survophthal.2004.01.004
- 식품의약품안전청 : 의약품 등 정보. Available at http://ezdrug.kfda.go.kr/kfda2 (Accessed October 23, 2009).
- Karpecki, P., Depaolis, M., Hunter, J. A., White, E. M., Rigel, L., Brunner, L. S., Usner, D. W., Paterno, M. R. and Comstock, T. L. : Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin. Ther. 31, 514 (2009). https://doi.org/10.1016/j.clinthera.2009.03.010
- Szaflik, J., Szaflik, J. P. and Kaminska, A. : Levofloxacin bacterial conjunctivitis dosage study group. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur. J. Ophthalmol. 19, 1 (2009).
- Yee, R. W., Tepedino, M., Bernstein, P., Jensen, H., Schiffman, R. and Whitcup, S. M. : Gatifloxacin BID/QID study group: A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. Curr. Med. Res. Opin. 21, 425 (2005). https://doi.org/10.1185/030079905X30699
- Hwang, D. G., Schanzlin, D. J., Rotberg, M. H., Foulks, G. and Raizman, M. B. : Levofloxacin bacterial conjunctivitis placecontrolled study group: A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br. J. Ophthalmol. 87, 1004 (2003). https://doi.org/10.1136/bjo.87.8.1004
- Schwab, I. R., Friedlaender, M., McCulley, J., Lichtenstein, S. J. and Moran, C. T. : Levofloxacin bacterial conjunctivitis active control study group: A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110, 457 (2003). https://doi.org/10.1016/S0161-6420(02)01894-8
- Tabbara, K. F., El-Sheikh, H. F., Islam, S. M. and Hammouda, E. : Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. Eur. J. Ophthalmol. 9, 269 (1999). https://doi.org/10.1177/112067219900900403
- Gross, R. D., Hoffman, R. O. and Lindsay, R. N. : A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin. Pediatr. (Phila). 36, 435 (1997). https://doi.org/10.1177/000992289703600801
- Adenis, J. P., Brasseur, G., Demailly, P., Malet, F., Verin, P., Saint-Blancat, P., Retout, A., Oll, P. and Colin, J. : Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions. Eur. J. Ophthalmol. 6, 287 (1996).
- Adenis, J. P., Colin, J., Verin, P., Saint-Blancat, P. and Malet, F. : Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. Eur. J. Ophthalmol. 5, 82 (1995).
- Gwon, A. : Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. Br. J. Ophthalmol. 76, 714 (1992). https://doi.org/10.1136/bjo.76.12.714
- Gwon, A. : Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol. 110, 1234 (1992). https://doi.org/10.1001/archopht.1992.01080210052022
- Bron, A. J., Leber, G., Rizk, S. N., Baig, H., Elkington, A. R., Kirkby, G. R., Neoh, C., Harden, A. and Leong, T. : Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br. J. Ophthalmol. 75, 675 (1991). https://doi.org/10.1136/bjo.75.11.675
- Leibowitz, H. M. : Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am. J. Ophthalmol. 112, 29S (1991).
- Schlech, B. A. and Blondeau, J. : Future of ophthalmic antiinfective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv. Ophthalmol. 50, S64 (2005). https://doi.org/10.1016/j.survophthal.2005.05.005
- Bertino, J. S. and Zhang, J. : Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Expert Opinion on Pharmacotherapy 10, 2545 (2009). https://doi.org/10.1517/14656560903213413